ORTHOCLONE OKT3 Drug Profile

Summary for Tradename: ORTHOCLONE OKT3

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ORTHOCLONE OKT3 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ORTHOCLONE OKT3 Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ORTHOCLONE OKT3 Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Centocor Ortho Biotech Products, L.p.	ORTHOCLONE OKT3	muromanab-cd3	Injection	103463	10,813,917	2030-12-10	Patent claims search
Centocor Ortho Biotech Products, L.p.	ORTHOCLONE OKT3	muromanab-cd3	Injection	103463	6,133,324	2019-05-06	Patent claims search
Centocor Ortho Biotech Products, L.p.	ORTHOCLONE OKT3	muromanab-cd3	Injection	103463	6,956,041	2023-08-13	Patent claims search
Centocor Ortho Biotech Products, L.p.	ORTHOCLONE OKT3	muromanab-cd3	Injection	103463	7,071,158	2021-02-07	Patent claims search

Market Dynamics and Financial Trajectory of ORTHOCLONE OKT3

Last updated: February 20, 2026

What is ORTHOCLONE OKT3?

ORTHOCLONE OKT3 (muromonab-CD3) is a monoclonal antibody developed for immunosuppressive therapy, primarily used to prevent organ transplant rejection. Approved by FDA in 1986, it targets the CD3 receptor on T cells, leading to T cell depletion. Its indication is limited under current regulatory status, with usage declining due to newer therapies.

How has the market evolved since its approval?

The initial market for ORTHOCLONE OKT3 expanded rapidly following FDA approval in 1986, driven by the need for effective rejection prevention post-transplant. In its peak years, the drug was a standard for acute rejection episodes in kidney, liver, and heart transplants, capturing a significant share of immunosuppressive biologics.

However, over the past decade, its market share has diminished, attributable to:

• Emergence of biologics targeting other immune pathways.
• Introduction of Bispecific T-cell Engagers (BiTEs) and immune checkpoint inhibitors.
• Shift towards therapies with more favorable safety profiles.

The global transplant immunosuppressive biologics market was valued at approximately $2.5 billion in 2021, with ORTHOCLONE OKT3 comprising less than 5% of total sales.

What are the current market drivers and barriers?

Drivers:

• Rare Indications and Niche Use Cases: Some transplant centers still employ ORTHOCLONE OKT3 for refractory rejection episodes.
• Regulatory Designations: Orphan drug status in certain regions can delay market exit, incentivizing niche use.

Barriers:

• Toxicity Profile: Notably, cytokine release syndrome and increased infection risk limit broader adoption.
• Manufacturing Constraints: Complexity in monoclonal antibody production escalates costs.
• Competition: Availability of newer agents such as basiliximab and ATG facilitates replacement of OKT3.

Regulatory and Reimbursement Environment:

• FDA Classification: Still approved for specific rejection indications, though its use is often off-label.
• Pricing: Historically high, but declining due to reduced demand and patent expiry in regions lacking exclusivity.

What is the financially relevant timeline?

Patent and Exclusivity:

• The original patent expired in the U.S. in 1994.
• No current patent protection exists.
• Limited exclusivity through orphan drug status in certain jurisdictions has expired or is expiring soon.

Revenue Trends:

Year	Approximate Revenue (USD millions)	Notes
2010	30	Declining market share
2015	12	Replacement therapies gaining ground
2020	4	Minimal sales for niche indications
2023	Below 1	Largely phased out from mainstream use

Future Outlook:

• The drug is expected to continue its decline absent new indications or formulations.
• Market exit considerations hinge on manufacturing costs versus residual niche demand.

How do competitive products influence the market?

Newer biologics like basiliximab (Simulect), which inhibits IL-2 receptor, offer fewer side effects and improved safety. Preclinical advances and better pharmacokinetics have lessened the niche for ORTHOCLONE OKT3.

What are the risks confronting remaining market activity?

• Regulatory withdrawal due to safety concerns.
• Loss of acceptance amid high manufacturing costs.
• Potential for legal or patent challenges in regions where orphan designations may be exhausted.

What is the outlook for investors or stakeholders?

Residual use in select transplants sustains minimal revenue. Divestment or licensing diminishes the risk of continued manufacturing liabilities. Absent clinical or regulatory repositioning, the financial trajectory shows a clear decline towards obsolescence.

---

Key Takeaways

• ORTHOCLONE OKT3 peaked in the late 1980s, shrinking to niche use today.
• The global transplant biologics market is approximately $2.5 billion; ORTHOCLONE OKT3's share is negligible.
• Diminishing revenue, expired patents, and regulatory limits drive accelerated phase-out.
• Competition from newer, safer biologics inhibits market recovery.
• Future valuation depends on residual demand, manufacturing costs, and regulatory decisions.

---

FAQs

1. Will ORTHOCLONE OKT3 ever regain market share?
Unlikely. The drug's safety profile and competition from newer biologics diminish prospects for significant market re-entry.

2. Are there ongoing clinical trials involving ORTHOCLONE OKT3?
Few, primarily to assess its role in refractory rejection cases, but most research has shifted to novel agents.

3. Could ORTHOCLONE OKT3 be reformulated for new indications?
Potentially, but significant investment in R&D and regulatory approval would be necessary. No current signals suggest this effort.

4. What are the manufacturing and supply risks?
Limited production capacity and higher costs relative to modern manufacturing can result in supply constraints and economic obsolescence.

5. How does ORTHOCLONE OKT3 compare financially to other biologics?
Compared to blockbuster biologics like Humira ($21 billion revenue in 2020), ORTHOCLONE OKT3's revenue is negligible and declining.

---

References

1. U.S. Food and Drug Administration (FDA). (2022). ORTHOCLONE OKT3 (muromonab-CD3) approval history.
2. MarketWatch. (2022). Global transplant immunosuppressive biologics market size & share.
3. PharmaSphere. (2023). Biological therapies in transplantation.
4. World Health Organization (WHO). (2022). Biologic medicines patent landscape.
5. Statista. (2023). Revenue figures for biologic drugs by mechanism of action.